Javelin BRCA/ATM: Avelumab Plus Talazoparib in Patients With BRCA or ATM Mutant Solid Tumors

NCT03565991 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

202

Enrollment

INDUSTRY

Sponsor class

Stopped The study was terminated since there was no need for further safety or efficacy data to be collected. The participants having benefit from the investigational treatments have been moved to a continuation study (NCT05059522)

Conditions

Locally Advanced or Metastatic Solid Tumors
Genes, BRCA 1

Interventions

DRUG: Avelumab
DRUG: Talazoparib

Sponsor

Pfizer